查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1615477

HIV 疫苗市场：按阶段、类别、抗体、最终用户 - 2025-2030 年全球预测

HIV Vaccines Market by Phase (Phase I, Phase II, Phase III), Category (Preventive Vaccines, Therapeutic Vaccines), Antibodies, End Users - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年HIV疫苗市场价值为83508万美元，预计2024年将达到94005万美元，复合年增长率为12.88%，到2030年将达到195126万美元。

HIV疫苗市场的范围和定义包括旨在预防人类免疫力缺乏病毒（HIV）感染的疫苗的开发、生产和分销。 HIV/爱滋病对全球数百万人的持续影响以及目前缺乏抗逆转录病毒治疗和暴露前预防 (PrEP) 等预防措施的有效性有限，推动了对 HIV 疫苗的需求。主要用途是高危险群，例如医护人员、有高危险性行为的个人、爱滋病毒流行率高的地区。最终使用领域包括希望将这些疫苗纳入更广泛的公共卫生策略的医院、研究机构和社区健康中心。推动市场成长的主要因素包括研发方面的大量投资、意识的提高、政府激励以及生物技术的进步，这些因素导致生物技术公司利用公共卫生服务来推进临床试验。潜在的商机在于老牌製药公司和创新生物技术公司之间扩大合作，利用基因工程和合成生物学来创造更有效的候选疫苗。抓住这些机会的建议包括加强策略联盟和增加突破性临床试验的资助。然而，市场成长受到不断上升的研发成本、复杂的监管核准流程、临床实验人群的道德考虑以及疫苗分配和管理的困难（尤其是在资源有限的环境下）的阻碍。为了克服这些挑战，公司必须专注于创新领域，例如 mRNA 疫苗技术（该技术已在其他病毒感染疾病中显示功效）以及针对不同人群遗传标记的个人化疫苗。市场考虑表明，创新的紧迫性加剧了竞争，但透过共用的全球健康目标培育的协作生态系统平衡了竞争。优先考虑永续实践和公平获取不仅能带来业务成长，还能对全球健康产生变革性影响。

主要市场统计
基准年[2023] 83508万美元
预计年份 [2024] 94005万美元
预测年份 [2030] 1,951.26 百万美元
复合年增长率（%） 12.88%

市场动态：揭示快速发展的爱滋病疫苗市场的关键市场洞察

供需的动态交互作用正在改变爱滋病毒疫苗市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助消费行为及其对製造业的影响。

  • 市场驱动因素
    • 全世界对爱滋病的认识不断提高以及对有效治疗的需求
    • 政府对爱滋病治疗药物的支持体系与政策
    • 政府和非政府组织加强针对爱滋病毒流行的宣传活动
  • 市场限制因素
    • 与爱滋病毒疫苗商业化和标准化相关的严格法规
  • 市场机会
    • 利用 CRISPR 基因编辑和人工智慧进行 HIV 预测模型的创新
    • 政府机构和生技公司之间的研发伙伴关係关係增加
  • 市场挑战
    • 与配方和产品召回案例相关的复杂性

波特五力：引领爱滋病疫苗市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解 HIV 疫苗市场的外部影响

外部宏观环境因素在塑造爱滋病疫苗市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解爱滋病疫苗市场的竞争格局

HIV 疫苗市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵 HIV 疫苗市场供应商绩效评估

FPNV定位矩阵是评估HIV疫苗市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议绘製爱滋病疫苗市场的成功之路

HIV 疫苗市场的策略分析对于旨在加强其在全球市场的影响力的公司至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 世界各地对爱滋病的认识不断提高，对有效治疗的需求也随之增加。
      • 政府对爱滋病毒药物的支持框架与政策
      • 政府和非政府组织加强宣传活动，提高人们对爱滋病毒流行的认识
    • 抑制因素
      • 与爱滋病毒疫苗商业化和标准化相关的严格法规
    • 机会
      • CRISPR 基因编辑和人工智慧驱动的 HIV 预测模型的创新
      • 政府机构和生技公司之间的研发伙伴关係关係增加
    • 任务
      • 药品处方和产品召回案例的复杂性
  • 市场区隔分析
    • 阶段：分几个阶段对爱滋病毒疫苗进行严格测试，以确保公众健康
    • 最终用户：在公共保健机构中广泛使用爱滋病毒疫苗以控制和消除爱滋病毒流行
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章 HIV 疫苗市场分阶段

  • 第一阶段
  • 第二阶段
  • 第三阶段

第七章 HIV 疫苗市场：依类别

  • 预防性疫苗
  • 治疗性疫苗

第八章 HIV 疫苗市场（按抗体）

  • 10E8
  • 广泛中和抗体
  • PG9 和 PG16
  • ＶＲＣ０１

第九章 HIV 疫苗市场：依最终用户分类

  • 临床研究中心
  • 医院
  • 公立医疗机构

第10章美洲HIV疫苗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太HIV疫苗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章 欧洲、中东和非洲HIV疫苗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • Uvax Bio 在澳洲透过临床试验推进 HIV 疫苗的开发
    • FDA核准新型 HIV 疫苗 HB-500 的人体试验
    • Absai 与加州理工学院之间的创新合作开发出负担得起的爱滋病毒治疗疫苗
  • 战略分析和建议

公司名单

  • AlphaVax, Inc.
  • Antigen Express, Inc. by Generex Biotechnology Corporation
  • Argos Therapeutics, Inc.
  • Bavarian Nordic
  • Bionor Holding AS
  • Celldex Therapeutics, Inc.
  • GeneCure LLC
  • Genetic Immunity, Inc.
  • GenVec, Inc.
  • GeoVax Labs, Inc.
  • GlaxoSmithKline PLC
  • Immune Response BioPharma, Inc.
  • Inovio Pharmaceuticals, Inc.
  • Johnson & Johnson
  • Moderna Inc.
  • Novartis AG
  • Oncolys BioPharma Inc.
  • Sanofi SA
  • TVAX Biomedical, Inc.
Product Code: MRR-4312A385A507

The HIV Vaccines Market was valued at USD 835.08 million in 2023, expected to reach USD 940.05 million in 2024, and is projected to grow at a CAGR of 12.88%, to USD 1,951.26 million by 2030.

The scope and definition of the HIV vaccines market encompass the development, production, and distribution of vaccines aimed at preventing Human Immunodeficiency Virus (HIV) infections. The necessity for HIV vaccines arises from the continuous global impact of HIV/AIDS, with millions affected worldwide, and the limited effectiveness of current preventive measures like antiretroviral therapies and pre-exposure prophylaxis (PrEP). The primary applications involve their use in at-risk populations, including healthcare workers, individuals with high-risk sexual behavior, and regions with high HIV prevalence. End-use scopes include hospitals, research institutes, and community health centers aiming to integrate these vaccines into broader public health strategies. Key factors driving market growth include substantial investments in R&D, rising awareness, and government incentivization, alongside advancements in biotechnology, which foster biotechnology companies to partner with public health organizations to advance clinical trials. Potential opportunities lie in the growing collaborations between established pharmaceutical firms and innovative biotechs, leveraging genetic engineering and synthetic biology to create more effective vaccine candidates. Recommendations to seize these opportunities include enhancing strategic alliances and increasing funding towards groundbreaking clinical trials. However, market growth is hampered by high R&D costs, complex regulatory approval processes, and ethical considerations in trial populations, as well as logistical challenges in ensuring vaccine distribution and administration, especially in resource-limited settings. To overcome these, businesses must focus on areas of innovation such as mRNA vaccine technologies, which have shown efficacy in other viral infections, and personalized vaccines tailored to genetic markers of diverse populations. Insights into the market suggest a competitive nature intensified by the urgency to innovate, yet balanced by the collaborative ecosystem fostered by shared global health objectives. Prioritizing sustainable practices and equitable access promises not only business growth but also transformative health impacts on a global scale.

KEY MARKET STATISTICS
Base Year [2023] USD 835.08 million
Estimated Year [2024] USD 940.05 million
Forecast Year [2030] USD 1,951.26 million
CAGR (%) 12.88%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving HIV Vaccines Market

The HIV Vaccines Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing awareness about AIDS worldwide and the need for effective medications
    • Supportive government frameworks and policies for HIV drugs
    • Increasing number of government and NGO campaigns for awareness of the HIV epidemic
  • Market Restraints
    • Strict regulations associated with the commercialization and standardization of HIV vaccines
  • Market Opportunities
    • Technological innovations in CRISPR gene-editing and AI-driven predictive modeling for HIV
    • Increasing number of R&D partnerships between government bodies and biotechnology firms
  • Market Challenges
    • Complexities associated with drug formulation and cases of product recalls

Porter's Five Forces: A Strategic Tool for Navigating the HIV Vaccines Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the HIV Vaccines Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the HIV Vaccines Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the HIV Vaccines Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the HIV Vaccines Market

A detailed market share analysis in the HIV Vaccines Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the HIV Vaccines Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the HIV Vaccines Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the HIV Vaccines Market

A strategic analysis of the HIV Vaccines Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the HIV Vaccines Market, highlighting leading vendors and their innovative profiles. These include AlphaVax, Inc., Antigen Express, Inc. by Generex Biotechnology Corporation, Argos Therapeutics, Inc., Bavarian Nordic, Bionor Holding AS, Celldex Therapeutics, Inc., GeneCure LLC, Genetic Immunity, Inc., GenVec, Inc., GeoVax Labs, Inc., GlaxoSmithKline PLC, Immune Response BioPharma, Inc., Inovio Pharmaceuticals, Inc., Johnson & Johnson, Moderna Inc., Novartis AG, Oncolys BioPharma Inc., Sanofi S.A., and TVAX Biomedical, Inc..

Market Segmentation & Coverage

This research report categorizes the HIV Vaccines Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Phase, market is studied across Phase I, Phase II, and Phase III.
  • Based on Category, market is studied across Preventive Vaccines and Therapeutic Vaccines.
  • Based on Antibodies, market is studied across 10E8, Broadly Neutralizing Antibodies, PG9 and PG16, and VRC01.
  • Based on End Users, market is studied across Clinical Research Centers, Hospitals, and Public Healthcare Providers.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing awareness about AIDS worldwide and the need for effective medications
      • 5.1.1.2. Supportive government frameworks and policies for HIV drugs
      • 5.1.1.3. Increasing number of government and NGO campaigns for awareness of the HIV epidemic
    • 5.1.2. Restraints
      • 5.1.2.1. Strict regulations associated with the commercialization and standardization of HIV vaccines
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological innovations in CRISPR gene-editing and AI-driven predictive modeling for HIV
      • 5.1.3.2. Increasing number of R&D partnerships between government bodies and biotechnology firms
    • 5.1.4. Challenges
      • 5.1.4.1. Complexities associated with drug formulation and cases of product recalls
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Phase: Rigorous testing of HIV vaccines through several phases to ensure public health
    • 5.2.2. End Users: Extensive usage of HIV vaccines in public healthcare facilities to control and combat the HIV epidemic
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. HIV Vaccines Market, by Phase

  • 6.1. Introduction
  • 6.2. Phase I
  • 6.3. Phase II
  • 6.4. Phase III

7. HIV Vaccines Market, by Category

  • 7.1. Introduction
  • 7.2. Preventive Vaccines
  • 7.3. Therapeutic Vaccines

8. HIV Vaccines Market, by Antibodies

  • 8.1. Introduction
  • 8.2. 10E8
  • 8.3. Broadly Neutralizing Antibodies
  • 8.4. PG9 and PG16
  • 8.5. VRC01

9. HIV Vaccines Market, by End Users

  • 9.1. Introduction
  • 9.2. Clinical Research Centers
  • 9.3. Hospitals
  • 9.4. Public Healthcare Providers

10. Americas HIV Vaccines Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific HIV Vaccines Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa HIV Vaccines Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Uvax Bio Progresses HIV Vaccine Development with Australian Clinical Trial
    • 13.3.2. FDA Approves Novel HIV Vaccine, HB-500 Vaccine for Human Testing
    • 13.3.3. Innovative Collaboration Between Absci and Caltech to Develop Affordable HIV Therapeutic Vaccine
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AlphaVax, Inc.
  • 2. Antigen Express, Inc. by Generex Biotechnology Corporation
  • 3. Argos Therapeutics, Inc.
  • 4. Bavarian Nordic
  • 5. Bionor Holding AS
  • 6. Celldex Therapeutics, Inc.
  • 7. GeneCure LLC
  • 8. Genetic Immunity, Inc.
  • 9. GenVec, Inc.
  • 10. GeoVax Labs, Inc.
  • 11. GlaxoSmithKline PLC
  • 12. Immune Response BioPharma, Inc.
  • 13. Inovio Pharmaceuticals, Inc.
  • 14. Johnson & Johnson
  • 15. Moderna Inc.
  • 16. Novartis AG
  • 17. Oncolys BioPharma Inc.
  • 18. Sanofi S.A.
  • 19. TVAX Biomedical, Inc.

LIST OF FIGURES

  • FIGURE 1. HIV VACCINES MARKET RESEARCH PROCESS
  • FIGURE 2. HIV VACCINES MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL HIV VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL HIV VACCINES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL HIV VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL HIV VACCINES MARKET SIZE, BY PHASE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL HIV VACCINES MARKET SIZE, BY PHASE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL HIV VACCINES MARKET SIZE, BY CATEGORY, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL HIV VACCINES MARKET SIZE, BY CATEGORY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL HIV VACCINES MARKET SIZE, BY END USERS, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL HIV VACCINES MARKET SIZE, BY END USERS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS HIV VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS HIV VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES HIV VACCINES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES HIV VACCINES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. HIV VACCINES MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. HIV VACCINES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. HIV VACCINES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL HIV VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL HIV VACCINES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL HIV VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. HIV VACCINES MARKET DYNAMICS
  • TABLE 7. GLOBAL HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL HIV VACCINES MARKET SIZE, BY PHASE I, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL HIV VACCINES MARKET SIZE, BY PHASE II, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL HIV VACCINES MARKET SIZE, BY PHASE III, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL HIV VACCINES MARKET SIZE, BY PREVENTIVE VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL HIV VACCINES MARKET SIZE, BY THERAPEUTIC VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL HIV VACCINES MARKET SIZE, BY 10E8, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL HIV VACCINES MARKET SIZE, BY BROADLY NEUTRALIZING ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL HIV VACCINES MARKET SIZE, BY PG9 AND PG16, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL HIV VACCINES MARKET SIZE, BY VRC01, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL HIV VACCINES MARKET SIZE, BY CLINICAL RESEARCH CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL HIV VACCINES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL HIV VACCINES MARKET SIZE, BY PUBLIC HEALTHCARE PROVIDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS HIV VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES HIV VACCINES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 191. HIV VACCINES MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 192. HIV VACCINES MARKET, FPNV POSITIONING MATRIX, 2023